MA32901B1 - Composes utiles pour l'inhibition de la chk1 - Google Patents
Composes utiles pour l'inhibition de la chk1Info
- Publication number
- MA32901B1 MA32901B1 MA33944A MA33944A MA32901B1 MA 32901 B1 MA32901 B1 MA 32901B1 MA 33944 A MA33944 A MA 33944A MA 33944 A MA33944 A MA 33944A MA 32901 B1 MA32901 B1 MA 32901B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds useful
- inhibiting chk1
- chk1
- inhibiting
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention porte sur un composé aminopyrazole ou sur un sel de qualité pharmaceutique de celui-ci ou sur un solvate du sel, qui inhibe Chk1 et qui s'utilise dans le traitement du cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13817608P | 2008-12-17 | 2008-12-17 | |
| PCT/US2009/067437 WO2010077758A1 (fr) | 2008-12-17 | 2009-12-10 | Composés utiles pour inhiber chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32901B1 true MA32901B1 (fr) | 2011-12-01 |
Family
ID=42079067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33944A MA32901B1 (fr) | 2008-12-17 | 2011-06-14 | Composes utiles pour l'inhibition de la chk1 |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP2379532B1 (fr) |
| JP (1) | JP5705743B2 (fr) |
| KR (1) | KR101301777B1 (fr) |
| CN (1) | CN102245597B (fr) |
| AR (1) | AR074471A1 (fr) |
| AU (1) | AU2009333433B2 (fr) |
| BR (1) | BRPI0922468A2 (fr) |
| CA (1) | CA2746423C (fr) |
| CL (1) | CL2011001463A1 (fr) |
| CO (1) | CO6382122A2 (fr) |
| CR (1) | CR20110339A (fr) |
| CY (1) | CY1113930T1 (fr) |
| DK (1) | DK2379532T3 (fr) |
| DO (1) | DOP2011000185A (fr) |
| EA (1) | EA018118B1 (fr) |
| EC (1) | ECSP11011136A (fr) |
| ES (1) | ES2401558T3 (fr) |
| HK (1) | HK1160110A1 (fr) |
| HN (1) | HN2011001446A (fr) |
| HR (1) | HRP20130167T1 (fr) |
| IL (1) | IL213160A (fr) |
| JO (1) | JO2886B1 (fr) |
| MA (1) | MA32901B1 (fr) |
| MX (1) | MX2011006603A (fr) |
| MY (1) | MY156998A (fr) |
| NZ (1) | NZ593440A (fr) |
| PA (1) | PA8850801A1 (fr) |
| PE (1) | PE20120077A1 (fr) |
| PL (1) | PL2379532T3 (fr) |
| PT (1) | PT2379532E (fr) |
| RS (1) | RS52739B (fr) |
| SG (1) | SG172222A1 (fr) |
| SI (1) | SI2379532T1 (fr) |
| TN (1) | TN2011000298A1 (fr) |
| TW (1) | TWI436996B (fr) |
| UA (1) | UA101998C2 (fr) |
| WO (1) | WO2010077758A1 (fr) |
| ZA (1) | ZA201103946B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314108B2 (en) * | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
| JO3145B1 (ar) * | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| TWI725041B (zh) * | 2015-07-23 | 2021-04-21 | 美商美國禮來大藥廠 | 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 |
| TWI627168B (zh) * | 2015-12-07 | 2018-06-21 | 美國禮來大藥廠 | (s)-乳酸鹽 |
| CN108472293A (zh) * | 2015-12-15 | 2018-08-31 | 伊莱利利公司 | 用于癌症的联合疗法 |
| KR102159442B1 (ko) * | 2016-02-04 | 2020-09-24 | 파마엔진 인코포레이티드 | 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용 |
| JP2020512977A (ja) | 2017-03-31 | 2020-04-30 | シアトル ジェネティックス， インコーポレイテッド | Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ |
| EP3461480A1 (fr) | 2017-09-27 | 2019-04-03 | Onxeo | Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer |
| WO2021104461A1 (fr) * | 2019-11-29 | 2021-06-03 | 南京明德新药研发有限公司 | Dérivé de diazaindole et son utilisation en tant qu'inhibiteur de chk1 |
| WO2021119236A1 (fr) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Préparation d'un composé inhibiteur de chk1 |
| CN116546974A (zh) * | 2020-11-30 | 2023-08-04 | 住友制药株式会社 | 5-杂芳基-1h-吡唑-3-胺衍生物 |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| CN117715905A (zh) | 2021-05-27 | 2024-03-15 | 无界生物公司 | 检查点激酶1（chk1）抑制剂及其用途 |
| GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| KR20240128040A (ko) | 2021-12-24 | 2024-08-23 | 스미토모 파마 가부시키가이샤 | 2 고리성 골격을 갖는 1h-피라졸-3-아민 유도체 |
| WO2023229032A1 (fr) * | 2022-05-27 | 2023-11-30 | 住友ファーマ株式会社 | Agent thérapeutique pour le cancer réfractaire à un inhibiteur de point de contrôle immunitaire |
| JP7546104B2 (ja) | 2022-05-27 | 2024-09-05 | 住友ファーマ株式会社 | ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬 |
| GB202213792D0 (en) | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| GB202403910D0 (en) | 2024-03-19 | 2024-05-01 | Benovental Cambridge Ltd | New processes and intermediates for pharmaceutical products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| JP2006528661A (ja) * | 2003-07-25 | 2006-12-21 | ファイザー・インク | アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用 |
| WO2008117050A1 (fr) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazines pyrazolyl-amino substituées et utilisation de ces composés pour le traitement du cancer |
| US20090270418A1 (en) * | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
-
2009
- 2009-11-26 PA PA20098850801A patent/PA8850801A1/es unknown
- 2009-12-01 JO JO2009456A patent/JO2886B1/en active
- 2009-12-03 TW TW098141394A patent/TWI436996B/zh active
- 2009-12-03 AR ARP090104673A patent/AR074471A1/es not_active Application Discontinuation
- 2009-12-10 WO PCT/US2009/067437 patent/WO2010077758A1/fr active Application Filing
- 2009-12-10 SG SG2011044401A patent/SG172222A1/en unknown
- 2009-12-10 UA UAA201107564A patent/UA101998C2/ru unknown
- 2009-12-10 CA CA2746423A patent/CA2746423C/fr not_active Expired - Fee Related
- 2009-12-10 AU AU2009333433A patent/AU2009333433B2/en not_active Ceased
- 2009-12-10 ES ES09768586T patent/ES2401558T3/es active Active
- 2009-12-10 EP EP09768586A patent/EP2379532B1/fr active Active
- 2009-12-10 SI SI200930559T patent/SI2379532T1/sl unknown
- 2009-12-10 PL PL09768586T patent/PL2379532T3/pl unknown
- 2009-12-10 MY MYPI2011002767A patent/MY156998A/en unknown
- 2009-12-10 KR KR1020117013801A patent/KR101301777B1/ko active IP Right Grant
- 2009-12-10 MX MX2011006603A patent/MX2011006603A/es active IP Right Grant
- 2009-12-10 CN CN200980150018.7A patent/CN102245597B/zh active Active
- 2009-12-10 EA EA201170834A patent/EA018118B1/ru not_active IP Right Cessation
- 2009-12-10 PT PT97685861T patent/PT2379532E/pt unknown
- 2009-12-10 DK DK09768586.1T patent/DK2379532T3/da active
- 2009-12-10 PE PE2011001140A patent/PE20120077A1/es active IP Right Grant
- 2009-12-10 JP JP2011542264A patent/JP5705743B2/ja active Active
- 2009-12-10 NZ NZ593440A patent/NZ593440A/xx not_active IP Right Cessation
- 2009-12-10 BR BRPI0922468-8A patent/BRPI0922468A2/pt active Search and Examination
- 2009-12-10 RS RS20130153A patent/RS52739B/en unknown
-
2011
- 2011-05-26 IL IL213160A patent/IL213160A/en not_active IP Right Cessation
- 2011-05-27 ZA ZA2011/03946A patent/ZA201103946B/en unknown
- 2011-06-01 HN HN2011001446A patent/HN2011001446A/es unknown
- 2011-06-10 TN TN2011000298A patent/TN2011000298A1/fr unknown
- 2011-06-13 DO DO2011000185A patent/DOP2011000185A/es unknown
- 2011-06-14 MA MA33944A patent/MA32901B1/fr unknown
- 2011-06-15 CO CO11074829A patent/CO6382122A2/es active IP Right Grant
- 2011-06-16 EC EC2011011136A patent/ECSP11011136A/es unknown
- 2011-06-16 CL CL2011001463A patent/CL2011001463A1/es unknown
- 2011-06-17 CR CR20110339A patent/CR20110339A/es unknown
-
2012
- 2012-01-11 HK HK12100301.0A patent/HK1160110A1/xx unknown
-
2013
- 2013-02-27 HR HRP20130167AT patent/HRP20130167T1/hr unknown
- 2013-04-11 CY CY20131100305T patent/CY1113930T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32901B1 (fr) | Composes utiles pour l'inhibition de la chk1 | |
| TN2010000071A1 (en) | Fused imidazoles or cancer treatment | |
| EA201070786A1 (ru) | Бензофуропиримидиноны | |
| TN2011000293A1 (en) | Protein kinase inhibitors | |
| EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| WO2008022286A3 (fr) | petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase | |
| SG179418A1 (en) | Inhibitors of the hedgehog pathway | |
| MX2009003157A (es) | Pirazoliltienopiridinas terapeuticas. | |
| MX2010006241A (es) | Derivados de aminotriazol como agonistas de alx. | |
| WO2008036652A3 (fr) | Amidines servant de modulateurs d'indoléamine 2,3-dioxygénase | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
| ZA200806778B (en) | N-Hydroxyacrylamide compounds | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| MX2010007584A (es) | Inhibidores de proteina cinasa y uso de los mismos. | |
| UA85471C2 (ru) | Применение оксикодона для лечения висцеральной боли | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| WO2010062038A3 (fr) | Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant | |
| IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| WO2009011910A3 (fr) | Composés d'imidazolidinone, procédés pour inhiber une désubiquitination et procédés de traitement | |
| EA201390499A1 (ru) | Соединения, подходящие для ингибирования снк1 | |
| MA32628B1 (fr) | Agents antifongiques | |
| JO2999B1 (ar) | مركب ثلاثي حلقي و استخدامه الدوائي | |
| DE602008002598D1 (en) | Cyclohexylderivate | |
| WO2008050133A3 (fr) | Inhibition d'une agrégation de beta-amyloïde |